Basic Information

Gene symbol MAGEA10 Synonyms CT1.10, MAGE10 Type of gene protein-coding
Description MAGE family member A10

GTO ID GTC0344
Trial ID NCT02989064
Disease Head and Neck Squamous Cell Carcinoma | Melanoma | Urothelial Carcinoma
Altered gene MAGE-A10
Therapeutic/Target gene Target gene
TherapyTCR-T cell
Treatment ADP-A2M10
HLAHLA-A*02:01|HLA-A*02:06
PhasePhase1
Recruitment statusCompleted
TitlePhase 1 Cell Dose Escalation Study to Assess the Safety and Tolerability of Genetically Engineered MAGE-A10c796 T in HLA-A2+ Subjects With MAGE-A10 Positive Urothelial, Melanoma or Head and Neck Tumors
Year2016
CountryUnited States
Company sponsorAdaptimmune
Other ID(s)ADP-0022-004
Vector information
Vectorlentivirus
Transgene/Inserted genehigh-affinity melanoma-associated antigen (MAGE)-A10-specific T-cell receptor

Clinical Result

Cohort1: Head and neck SCC
Administration route infusion
Dosage 0.08~15E9 cells
Donor type autologous
Pts 4
Age Adult, Older_Adult
Lymph depletion Yes
Adverse reactions no TCR related AEs
References PMID: 35372008
Cohort2: Melanoma
Administration route infusion
Dosage 0.08~15E9 cells
Donor type autologous
Pts 3
Age Adult, Older_Adult
Lymph depletion Yes
Adverse reactions 1/3(CRS); 2/3(neurotoxicity); 2/3(Intermittent narcolepsy); 2/3(Attention disorder)
References PMID: 35372008
Cohort3: Urothelial Carcinoma
Administration route infusion
Dosage 0.08~15E9 cells
Donor type autologous
Pts 3
Age Adult, Older_Adult
Lymph depletion Yes
Adverse reactions 1/3(acute kidney injury); 1/3(maculopapule); 1/3(pancytopenia)
References PMID: 35372008

Relationship Graph

Overview of Knowledge Graph